Article

A cancer immunotherapy modality based on dendritic cell reprogramming <i>in vivo</i>

2024-07-11

Abstract excerpt

Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendri...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5dcd41c6-cd09-5f96-8fb8-d0313dab98f1
DOI: 10.1101/2024.07.08.602356

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A cancer immunotherapy modality based on dendritic cell reprogramming <i>in vivo</i>DOI 10.1101/2024.07.08.602356Read

Restoring tumor immunogenicity with dendritic cell reprogrammingSemantic proximity Read

Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cellsSemantic proximity Read

Understanding and Modulating Immunity With Cell ReprogrammingSemantic proximity Read

Cell Fate Reprogramming in the Era of Cancer ImmunotherapySemantic proximity Read

Direct reprogramming of fibroblasts into antigen-presenting dendritic cellsSemantic proximity Read

Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.Semantic proximity Read

Reprogramming Cancer into Antigen-Presenting Cells as a Novel ImmunotherapySemantic proximity Read

Rewiring dendritic cell function with CLEC9A and DEC205-based chimeric antigen receptorsSemantic proximity Read

Reprogramming the tumor microenvironment by genome editing for precision cancer therapySemantic proximity Read

Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined TherapiesSemantic proximity Read

Peptide-MHC-targeted retroviruses enable <i>in vivo</i> expansion and gene delivery to tumor-specific T cellsSemantic proximity Read

STING Licensing of Type I Dendritic Cells Potentiates Antitumor ImmunitySemantic proximity Read